Cargando…
Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory?
BACKGROUND: An increased risk of cardiovascular (CV) complications has been described in patients with rheumatoid arthritis (RA). It is the result of the combined effect of classic CV risk factors and others that are specific to the disease. METHODS: We assessed data from 448 early arthritis (EA) pa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488761/ https://www.ncbi.nlm.nih.gov/pubmed/32917272 http://dx.doi.org/10.1186/s13075-020-02307-8 |
_version_ | 1783581760029720576 |
---|---|
author | Fernández-Ortiz, Ana M. Ortiz, Ana M. Pérez, Silvia Toledano, Esther Abásolo, Lydia González-Gay, Miguel A. Castañeda, Santos González-Álvaro, Isidoro |
author_facet | Fernández-Ortiz, Ana M. Ortiz, Ana M. Pérez, Silvia Toledano, Esther Abásolo, Lydia González-Gay, Miguel A. Castañeda, Santos González-Álvaro, Isidoro |
author_sort | Fernández-Ortiz, Ana M. |
collection | PubMed |
description | BACKGROUND: An increased risk of cardiovascular (CV) complications has been described in patients with rheumatoid arthritis (RA). It is the result of the combined effect of classic CV risk factors and others that are specific to the disease. METHODS: We assessed data from 448 early arthritis (EA) patients: 79% women, age (median [p25-p75]) at onset: 55 [44–67] years and disease duration at study entry 5 [3–8] months; and 72% fulfilled the 1987 RA criteria at 2 years of follow-up. Rheumatoid factor was positive in 54% of patients and anti-citrullinated peptide antibodies in 50%. The follow-up of patients ranged from 2 to 5 years with more than 1400 visits with lipoprotein measurements available (mean 2.5 visits/patient). Demographic- and disease-related variables were systematically recorded. Total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) levels were obtained from routine laboratory tests. Oxidized-LDL (oxLDL-C) levels were assessed using a commercial ELISA kit. We fitted population-averaged models nested by patient and visit to determine the effect of independent variables on serum levels of TC, its fractions, and oxLDL-C. RESULTS: After adjustment for several confounders, high-disease activity was significantly associated with decreased TC, HDL-C, and LDL-C levels and increased oxLDL-C levels. Standardized coefficients showed that the effect of disease activity was greater on oxLDL-C and HDL-C. Interestingly, we observed that those patients with lower levels of LDL-C showed higher oxLDL-C/LDL-C ratios. CONCLUSIONS: High-disease activity in EA patients results in changes in the HDL-C and oxLDL-C levels, which in turn may contribute to the increased risk of CV disease observed in these patients. |
format | Online Article Text |
id | pubmed-7488761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-74887612020-09-16 Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? Fernández-Ortiz, Ana M. Ortiz, Ana M. Pérez, Silvia Toledano, Esther Abásolo, Lydia González-Gay, Miguel A. Castañeda, Santos González-Álvaro, Isidoro Arthritis Res Ther Research Article BACKGROUND: An increased risk of cardiovascular (CV) complications has been described in patients with rheumatoid arthritis (RA). It is the result of the combined effect of classic CV risk factors and others that are specific to the disease. METHODS: We assessed data from 448 early arthritis (EA) patients: 79% women, age (median [p25-p75]) at onset: 55 [44–67] years and disease duration at study entry 5 [3–8] months; and 72% fulfilled the 1987 RA criteria at 2 years of follow-up. Rheumatoid factor was positive in 54% of patients and anti-citrullinated peptide antibodies in 50%. The follow-up of patients ranged from 2 to 5 years with more than 1400 visits with lipoprotein measurements available (mean 2.5 visits/patient). Demographic- and disease-related variables were systematically recorded. Total cholesterol (TC), high-density lipoprotein (HDL-C), and low-density lipoprotein (LDL-C) levels were obtained from routine laboratory tests. Oxidized-LDL (oxLDL-C) levels were assessed using a commercial ELISA kit. We fitted population-averaged models nested by patient and visit to determine the effect of independent variables on serum levels of TC, its fractions, and oxLDL-C. RESULTS: After adjustment for several confounders, high-disease activity was significantly associated with decreased TC, HDL-C, and LDL-C levels and increased oxLDL-C levels. Standardized coefficients showed that the effect of disease activity was greater on oxLDL-C and HDL-C. Interestingly, we observed that those patients with lower levels of LDL-C showed higher oxLDL-C/LDL-C ratios. CONCLUSIONS: High-disease activity in EA patients results in changes in the HDL-C and oxLDL-C levels, which in turn may contribute to the increased risk of CV disease observed in these patients. BioMed Central 2020-09-11 2020 /pmc/articles/PMC7488761/ /pubmed/32917272 http://dx.doi.org/10.1186/s13075-020-02307-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Fernández-Ortiz, Ana M. Ortiz, Ana M. Pérez, Silvia Toledano, Esther Abásolo, Lydia González-Gay, Miguel A. Castañeda, Santos González-Álvaro, Isidoro Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? |
title | Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? |
title_full | Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? |
title_fullStr | Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? |
title_full_unstemmed | Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? |
title_short | Effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized LDL cholesterol explain the lipid paradox theory? |
title_sort | effects of disease activity on lipoprotein levels in patients with early arthritis: can oxidized ldl cholesterol explain the lipid paradox theory? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488761/ https://www.ncbi.nlm.nih.gov/pubmed/32917272 http://dx.doi.org/10.1186/s13075-020-02307-8 |
work_keys_str_mv | AT fernandezortizanam effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT ortizanam effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT perezsilvia effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT toledanoesther effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT abasololydia effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT gonzalezgaymiguela effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT castanedasantos effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory AT gonzalezalvaroisidoro effectsofdiseaseactivityonlipoproteinlevelsinpatientswithearlyarthritiscanoxidizedldlcholesterolexplainthelipidparadoxtheory |